Patents by Inventor Masami Yamada

Masami Yamada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180050996
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 22, 2018
    Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Takuto KOJIMA
  • Patent number: 9878989
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: January 30, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
  • Patent number: 9868725
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. (I) wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: January 16, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • Publication number: 20180000780
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: August 24, 2017
    Publication date: January 4, 2018
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • Publication number: 20170346962
    Abstract: A maintenance support device for supporting maintenance of an apparatus includes a communication interface configured to perform communication with the apparatus through a communication cable and to feed electric power to the apparatus; and an information obtaining portion configured to obtain from the apparatus, while the apparatus is fed with the electric power, pre-replacement individual identification information and post-replacement individual identification information for a target component for replacement work on the apparatus by communication using the communication interface.
    Type: Application
    Filed: May 22, 2017
    Publication date: November 30, 2017
    Applicant: KONICA MINOLTA, INC.
    Inventor: Masami YAMADA
  • Patent number: 9811294
    Abstract: A relay device includes a first session establishing portion to establish a first communication session with a cloud server located outside a firewall, a second session establishing portion to establish a second communication session with a control target device located inside the firewall, a device information acquiring portion to acquire device information about the control target device, and a relay portion to relay a communication between the cloud server and the control target device. The relay portion includes an executability determining portion to determine whether the control target device can execute a process specified by a control command received from the cloud server, a suspending portion to suspend an output of the control command when the determination result is non-executable, and a proxy transmission portion operable, when the determination result becomes executable after the control command was put on hold, to transmit the control command to the control target device.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: November 7, 2017
    Assignee: KONICA MINOLTA, INC.
    Inventors: Yasutaka Ito, Kazumi Sawayanagi, Noriaki Asamoto, Masami Yamada, Hisashi Uchida, Shuji Yoneda, Kazuya Anezaki, Akihiro Torigoshi
  • Patent number: 9789084
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: October 17, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • Patent number: 9789083
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: October 17, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • Patent number: 9775827
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: October 3, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • Patent number: 9777005
    Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa? or —N?; X2 is —CRb? or —N?; X3 is —CRc= or —N?; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: October 3, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Shinkichi Suzuki, Masami Yamada, Makoto Kamata, Takuto Kojima, Ikuo Fujimori, Kenichiro Shimokawa
  • Publication number: 20170279997
    Abstract: An image processing apparatus includes a display unit that displays a preview image of a document on a preview screen during login of a first user, a communication controller that receives a job from an external device, a determination unit that determines whether the job received from the external device is a specific type of job, and a display controller that controls display on the preview screen. When the specific type of job is received during display of the preview screen, the display controller assumes a predetermined degree or more of possibility that a second user different from the first user may approach the apparatus, and performs at least one of first display control where the preview image is automatically hidden on the preview screen and second display control where a non-display button for hiding the preview image according to a user operation is displayed on the preview screen.
    Type: Application
    Filed: March 17, 2017
    Publication date: September 28, 2017
    Applicant: Konica Minolta, Inc.
    Inventors: Kaitaku OZAWA, Katsuhiko AKITA, Yuji OKAMOTO, Masami YAMADA, Yuki ASAI, Kenichi TAKAHASHI, Yasutaka ITO
  • Publication number: 20170266162
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 21, 2017
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • Publication number: 20170258764
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 14, 2017
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • Publication number: 20170257504
    Abstract: An image processing apparatus includes a main processor configured to process packets received by a wired LAN module and a wireless LAN module in a normal state and a sub processor configured to process packets received by the wired LAN module and the wireless LAN module in place of the main processor in a first power saving state in which supply of electric power to the main processor is stopped. In the first power saving state, the sub processor is configured to process a packet received by the wired LAN module by using a first combination of a MAC address and an IP address and to process a packet received by the wireless LAN module by using a second combination of a MAC address and an IP address.
    Type: Application
    Filed: March 2, 2017
    Publication date: September 7, 2017
    Applicant: Konica Minolta, Inc.
    Inventors: Masami Yamada, Katsuhiko Akita, Kaitaku Ozawa, Yuji Okamoto, Yuki Asai, Kenichi Takahashi, Yasutaka Ito
  • Publication number: 20170244863
    Abstract: An information processing apparatus to which a plurality of users can log in includes: a display unit configured to display an image; and a display controller configured to display personal region images corresponding to the respective users in a plurality of personal display regions at different positions in a display face of the display unit, display common images in the same common display region among the users in the display face of the display unit, and display images of data acquired on the authority to access of a corresponding user in the personal display regions to be movable, respectively, wherein when any of the users logs out, the display controller finishes displaying the image arranged in the personal display region among the data acquired on the authority to access of the user who logs out, and continues to display the image arranged in the common display region.
    Type: Application
    Filed: February 23, 2017
    Publication date: August 24, 2017
    Applicant: Konica Minolta, Inc.
    Inventors: Kenichi Takahashi, Katsuhiko Akita, Kaitaku Ozawa, Masami Yamada, Yuji Okamoto, Yuki Asai, Yasutaka Ito
  • Patent number: 9732086
    Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa? or —N?; X2 is —CRb? or —N?; X3 is —CRc= or —N?; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: August 15, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Shinkichi Suzuki, Masami Yamada, Makoto Kamata, Takuto Kojima, Ikuo Fujimori, Kenichiro Shimokawa
  • Publication number: 20170216255
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • Patent number: 9675597
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: June 13, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • Patent number: 9662316
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: May 30, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • Patent number: 9655881
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: May 23, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata